Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies

17 de julho de 2026 atualizado por: Servier

A Phase 1/2, Open Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination With Other Antileukemic Agents in Participants With Selected Myeloid Malignancies

The objective of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of S241656 and to determine the recommended dose for expansion (RDE) of S241656 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML), myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), or chronic myelomonocytic leukemia (CMML). Part 1A dose escalation will determine the RDE to be used in a future expansion stage of the trial. An optional Part 1B drug-drug interaction (DDI) substudy will evaluate the effect of posaconazole on the PK of S241656.

The study consists of a screening period of up to 21 days, a treatment period consisting of continuous 28-day cycles of treatment, an end-of-treatment visit, a safety follow-up period, and long-term disease and survival follow-up every 3 months. Participants in the optional DDI substudy may continue treatment in the main study following completion of the DDI assessment period. Participants may undergo bone marrow aspirates and/or biopsies, blood tests, electrocardiograms (ECGs), echocardiograms or multigated acquisition (MUGA) scans, physical examinations, ophthalmologic assessments, and disease response questionnaires.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

64

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Descrição

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
  • Investigator-assessed life expectancy of ≥ 3 months.
  • Able and willing to comply with requirements of the study protocol.
  • Documented genetic characterization of the disease as per local practice.
  • Clinical and laboratory thresholds:
  • Cytoreduction: white blood cell (WBC) < 25 × 10⁹/L (hydroxyurea/cytarabine/leukapheresis allowed).
  • Renal: creatinine clearance (CrCl) ≥ 60 mL/min (Cockcroft-Gault).
  • Hepatic: aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN) (5 × if leukemic); Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN for Gilbert's syndrome).
  • Part 1 Only: Relapsed/Refractory (R/R), pathologically confirmed AML, MDS/AML, or CMML.
  • Part 1 Only: Must have failed ≥ 1 approved standard therapy and have no other approved standard options.

Exclusion Criteria:

  • Known hypersensitivity to S241656, or Posaconazole (Part 1B).
  • Pregnant or breastfeeding; positive serum pregnancy test for WOCBP.
  • Diagnosis of acute promyelocytic leukemia (French-American-British [FAB] M3 classification), MPN, mixed/ambiguous lineage, histiocytic/dendritic cell neoplasms, or AML with isolated extramedullary disease (no marrow/blood involvement).
  • Active Central Nervous System (CNS) disease (by cytologic or radiographic evidence).
  • Failure to recover to ≤ Grade 1 from previous toxicities (except Grade 2 neuropathy/alopecia).
  • Major surgery within 4 weeks.
  • Any anticancer therapy within 2 weeks or 5 half-lives (28 days for biologics). Cytoreduction with hydroxyurea or cytarabine is permitted.
  • Prior use of experimental KRAS/BRAF/MEK/ERK inhibitors (prior FLT3 inhibitors are permitted).
  • Uncontrolled infections (human immunodeficiency virus (HIV)/hepatitis B virus (HBV)/hepatitis C virus (HCV) permitted only if viral load is undetectable/controlled and specific cluster of differentiation 4 (CD4)+ criteria are met).
  • Malabsorption, Crohn's, or chronic vomiting that impacts oral drug absorption.
  • History/risk of retinal vein occlusion (RVO), glaucoma, or hyper-viscosity syndromes.
  • Other active malignancy requiring systemic therapy within 2 years (except non-melanoma skin cancer or localized/cured tumors).
  • Stroke, myocardial infarction (MI), unstable angina, or acute coronary syndrome within 6 months.
  • Congestive heart failure (CHF), clinically significant cardiac arrhythmias according to the investigator's judgement (e.g., ventricular tachycardia), complete left bundle branch block and high-grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II- and third degree AV block).
  • Fridericia-corrected QT interval (QTcF) > 470 msec or history of Torsades de pointes.
  • Disseminated intravascular coagulation (DIC), significant coagulopathy according to the investigator's judgement, or uncontrolled bleeding.
  • Proton Pump Inhibitors (PPIs) and potassium-competitive acid blockers ≥ 7 days prior to Cycle 1 Day 1.
  • Breast cancer resistance protein (BCRP) sensitive substrate or with a narrow therapeutic index (NTI)
  • All herbal preparations/supplements are prohibited.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Part 1A: Dose Escalation
Tablets taken by mouth.
Experimental: Part 1B: Optional Drug-Drug Interaction [DDI] Substudy
Tablets taken by mouth.
Tablets taken by mouth

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Prazo
(Part 1A and 1B) Dose limiting toxicity (DLTs) associated with S241656 during the first cycle of treatment
Prazo: Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1A and 1B) Number of Adverse Events (AEs)
Prazo: Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Number of Serious Adverse Events (SAEs)
Prazo: Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Severity of AEs
Prazo: Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Severity of SAEs
Prazo: Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Duration of AEs
Prazo: Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Duration of SAEs
Prazo: Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Number of changes in safety laboratory results
Prazo: Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Number of changes in physical examination
Prazo: Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Number of dose reductions due to AEs
Prazo: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A and 1B) Number of dose interruptions due to AEs
Prazo: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A and 1B) Number of dose delays due to AEs
Prazo: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A and 1B) Number of study withdrawals due to AEs
Prazo: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1B only) Maximum concentration (Cmax) of S241656
Prazo: Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1B only) Cmax of metabolite S243796
Prazo: Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1B only) Time corresponding to Cmax (Tmax) of S241656
Prazo: Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1B only) Tmax of metabolite S243796
Prazo: Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1B only) Terminal half-life (t1/2) of S241656
Prazo: Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1B only) t1/2 of metabolite S243796
Prazo: Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1B only) Area under the curve (AUC) of S241656
Prazo: Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1B only) AUC of metabolite S243796
Prazo: Through Cycle 1 (28 days)
Through Cycle 1 (28 days)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
(Part 1A only) Cmax of S241656
Prazo: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A only) Cmax of metabolite S243796
Prazo: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A only) Tmax of S241656
Prazo: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A only) Tmax of metabolite S243796
Prazo: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A only) AUC of S241656
Prazo: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A only) AUC of metabolite S243796
Prazo: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A only) t1/2 of S241656
Prazo: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A only) t1/2 of metabolite S243796
Prazo: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A and 1B) Complete remission (CR)
Prazo: Through study completion, approximately 4 years
Through study completion, approximately 4 years
(Part 1A and 1B) Complete remission with incomplete hematologic recovery (CRi)
Prazo: Through study completion, approximately 4 years
In participants with AML or MDS/AML only
Through study completion, approximately 4 years
(Part 1A and 1B) Morphologic leukemia free state (MLFS)
Prazo: Through study completion, approximately 4 years
In participants with AML or MDS/AML only
Through study completion, approximately 4 years
(Part 1A and 1B) Complete remission with partial hematologic recovery (CRh)
Prazo: Through study completion, approximately 4 years
In participants with AML or MDS/AML only
Through study completion, approximately 4 years
(Part 1A and 1B) Partial response (PR)
Prazo: Through study completion, approximately 4 years
Through study completion, approximately 4 years
(Part 1A and 1B) Objective response (OR)
Prazo: Through study completion, approximately 4 years
Through study completion, approximately 4 years
(Part 1A and 1B) Composite complete remission (CRc)
Prazo: Through study completion, approximately 4 years
In participants with AML or MDS/AML only
Through study completion, approximately 4 years
(Part 1A and 1B) Red blood cell (RBC) and platelet transfusion independence for at least 8 weeks
Prazo: Through end of treatment, up to approximately 4 years
In participants with AML or MDS/AML only
Through end of treatment, up to approximately 4 years
(Part 1A and 1B) Duration of response (DOR)
Prazo: Through study completion, approximately 4 years
Through study completion, approximately 4 years
(Part 1A and 1B) Time to response (TTR)
Prazo: Through study completion, approximately 4 years
In participants with AML or MDS/AML only
Through study completion, approximately 4 years
(Part 1A and 1B) Event free survival (EFS)
Prazo: Through study completion, approximately 4 years
In participants with AML or MDS/AML only
Through study completion, approximately 4 years
(Part 1A and 1B) Overall survival (OS)
Prazo: Through study completion, approximately 4 years
Through study completion, approximately 4 years
(Part 1A and 1B) Marrow response
Prazo: Through end of treatment, up to approximately 4 years
In participants with CMML only
Through end of treatment, up to approximately 4 years
(Part 1A and 1B) Number of participants with erythroid-, neutrophil-, platelet or spleen-response
Prazo: Through end of treatment, up to approximately 4 years
In participants with CMML only
Through end of treatment, up to approximately 4 years

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

15 de setembro de 2026

Conclusão Primária (Estimado)

1 de novembro de 2027

Conclusão do estudo (Estimado)

30 de setembro de 2030

Datas de inscrição no estudo

Enviado pela primeira vez

8 de julho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

17 de julho de 2026

Primeira postagem (Real)

22 de julho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

22 de julho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

17 de julho de 2026

Última verificação

1 de julho de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.

Access can be requested for all interventional clinical studies:

  • used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
  • where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.

In addition, access can be requested for all interventional clinical studies in patients:

  • sponsored by Servier
  • with a first patient enrolled as of 1 January 2004 onwards
  • for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

Prazo de Compartilhamento de IPD

After Marketing Authorization in EEA or US if the study is used for the approval.

Critérios de acesso de compartilhamento IPD

Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CIF
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever